Literature DB >> 31728104

Apremilast in Refractory Alopecia Areata.

Andrea Estébanez1, Nuria Estébanez2, Jose M Martín1, Encarna Montesinos1.   

Abstract

Alopecia areata (AA) is a common disease characterized by nonscarring hair loss. There are no satisfactory therapies for extensive cases. Systemic immune suppressants are usually used despite their nonspecific actions and often associated side effects. Apremilast is an oral, small-molecule, inhibitor of phosphodiesterase 4 approved for the treatment of psoriasis and psoriatic arthritis. Its use in AA has shown variable results. Whereas a recent reduced clinical trial concluded a lack of efficacity, several case reports demonstrate a significant improvement. We report four cases of extensive AA successfully treated with apremilast. Copyright:
© 2019 International Journal of Trichology.

Entities:  

Keywords:  Alopecia areata; alopecia; apremilast

Year:  2019        PMID: 31728104      PMCID: PMC6830030          DOI: 10.4103/ijt.ijt_59_19

Source DB:  PubMed          Journal:  Int J Trichology        ISSN: 0974-7753


  9 in total

Review 1.  Alopecia areata update.

Authors:  S Madani; J Shapiro
Journal:  J Am Acad Dermatol       Date:  2000-04       Impact factor: 11.527

2.  The PDE4 inhibitor, apremilast, suppresses experimentally induced alopecia areata in human skin in vivo.

Authors:  Aviad Keren; Avner Shemer; Yehuda Ullmann; Ralf Paus; Amos Gilhar
Journal:  J Dermatol Sci       Date:  2014-12-03       Impact factor: 4.563

3.  Improvement of alopecia areata with apremilast.

Authors:  Jorge Magdaleno-Tapial; Cristian Valenzuela-Oñate; José Luis Sánchez-Carazo; Víctor Alegre-de Miquel
Journal:  Australas J Dermatol       Date:  2018-10-07       Impact factor: 2.875

Review 4.  Advances in the management of alopecia areata.

Authors:  Taisuke Ito
Journal:  J Dermatol       Date:  2012-01       Impact factor: 4.005

Review 5.  A novel therapeutic paradigm for patients with extensive alopecia areata.

Authors:  Yael Renert-Yuval; Emma Guttman-Yassky
Journal:  Expert Opin Biol Ther       Date:  2016-05-30       Impact factor: 4.388

6.  A randomized placebo-controlled single-center pilot study of the safety and efficacy of apremilast in subjects with moderate-to-severe alopecia areata.

Authors:  Daniela Mikhaylov; Ana Pavel; Christopher Yao; Grace Kimmel; John Nia; Peter Hashim; Anjali S Vekaria; Mark Taliercio; Giselle Singer; Rachel Karalekas; Danielle Baum; Yasaman Mansouri; Mark G Lebwohl; Emma Guttman-Yassky
Journal:  Arch Dermatol Res       Date:  2018-11-11       Impact factor: 3.017

Review 7.  Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.

Authors:  Lazaros I Sakkas; Athanasios Mavropoulos; Dimitrios P Bogdanos
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

8.  Apremilast (Otezla): A New Oral Treatment for Adults With Psoriasis and Psoriatic Arthritis.

Authors:  Tina Zerilli; Eric Ocheretyaner
Journal:  P T       Date:  2015-08

Review 9.  New developments in the management of psoriasis and psoriatic arthritis: a focus on apremilast.

Authors:  Andrew C Palfreeman; Kay E McNamee; Fiona E McCann
Journal:  Drug Des Devel Ther       Date:  2013-03-27       Impact factor: 4.162

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.